Phytomedicine Plus (Feb 2022)
Bioactive component of aqueous extract of Solanum melongena ameliorate estradiol valerate induced ovarian-pituitary dysfunctions in female Sprague–Dawley rats: Histomorphological and biochemical evidence
Abstract
Background: Estradiol valerate (EV) is known to cause hypothalamic-pituitary dysregulation of the gonadotrophin-releasing hormone. This study focused on the impact of aqueous extract of Solanum melongena (SM) on EV-induced ovarian-pituitary dysfunction in female Sprague-Dawley rats. Methods: Thirty-two healthy female Sprague Dawley rats weighing (8 weeks old; weight 150–200 g) were randomly divided into four groups of eight (n = 8) rats each. Group A received 2 ml of distilled water, Group B received a single dose of 4 mg/kg body weight (bwt) of EV (i.p), Group C received 500 mg/kg bwt SM extract orally and Group D received a single dose of 4 mg/kg bwt of EV (i.p) and 500 mg/kg bwt of SM orally, the experiment lasted for 21days. The following parameters body weight, pituitary gland weight, ovary weight, ovary, and pituitary gland histomorphology, total antioxidant status (TOS), total oxidant status (TOS), oxidative stress index (OSI), total cholesterol (TC), triglyceride, low-density lipoprotein (LDL), and high-density lipoprotein (HDL), progesterone, FSH, LH, Testosterone, and estradiol were assessed. Results: Estradiol valerate decreases the number of healthy follicles, progesterone, estradiol, HDL, and TAS. And increase degenerated cystic follicles, TT, FSH, LH, triglyceride, TC, LAL, TOS, and OSI. Pituitary gland showed degenerative changes, characterized by neutrophil infiltrations and loss of cellular projections marked improvement was observed in the ovary, pituitary gland, hormone, and biochemical parameters after SM administration. Conclusion: Solanum melongena offers protection against EV-induced ovarian-pituitary dysfunctions evidence by restoration of oxidative stress markers, steroidogenesis, and histopathological alterations back to control level.
